These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 8097906

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ, Chow YK, Caliendo AM, Videler J, Devore KM, Cooley TP, Liebman HA, Kaplan JC, Hirsch MS, D'Aquila RT.
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
    [Abstract] [Full Text] [Related]

  • 5. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA.
    Science; 1991 Sep 27; 253(5027):1557-9. PubMed ID: 1716788
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J.
    AIDS; 1996 Jun 27; 10(6):625-33. PubMed ID: 8780817
    [Abstract] [Full Text] [Related]

  • 11. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B, Pellegrin I, Ruffault A, Ragnaud JM, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJ.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr 01; 8(4):330-4. PubMed ID: 7533640
    [Abstract] [Full Text] [Related]

  • 12. Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.
    Shafer RW, Kozal MJ, Katzenstein DA, Lipil WH, Johnstone IF, Merigan TC.
    J Virol Methods; 1993 Mar 01; 41(3):297-310. PubMed ID: 8097199
    [Abstract] [Full Text] [Related]

  • 13. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.
    McLeod GX, McGrath JM, Ladd EA, Hammer SM.
    Antimicrob Agents Chemother; 1992 May 01; 36(5):920-5. PubMed ID: 1510414
    [Abstract] [Full Text] [Related]

  • 14. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S, La Seta Catamancio S, Sheridan F, Parker D.
    J Clin Virol; 2000 Dec 01; 19(3):135-42. PubMed ID: 11090748
    [Abstract] [Full Text] [Related]

  • 15. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.
    J Pediatr; 1998 Oct 01; 133(4):500-8. PubMed ID: 9787687
    [Abstract] [Full Text] [Related]

  • 16. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
    Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J, Eastman S.
    J Virol; 1995 Jun 01; 69(6):3510-6. PubMed ID: 7745698
    [Abstract] [Full Text] [Related]

  • 17. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.
    Frenkel LM, Wagner LE, Atwood SM, Cummins TJ, Dewhurst S.
    J Clin Microbiol; 1995 Feb 01; 33(2):342-7. PubMed ID: 7714190
    [Abstract] [Full Text] [Related]

  • 18. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.
    Demeter LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondelis P, Reichman RC.
    J Infect Dis; 1995 Dec 01; 172(6):1480-5. PubMed ID: 7594706
    [Abstract] [Full Text] [Related]

  • 19. Didanosine.
    Shelton MJ, O'Donnell AM, Morse GD.
    Ann Pharmacother; 1992 May 01; 26(5):660-70. PubMed ID: 1350471
    [Abstract] [Full Text] [Related]

  • 20. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups.
    Ragni MV, Amato DA, LoFaro ML, DeGruttola V, Van Der Horst C, Eyster ME, Kessler CM, Gjerset GF, Ho M, Parenti DM.
    Blood; 1995 May 01; 85(9):2337-46. PubMed ID: 7727768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.